Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
11 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
05 juin 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Alzheimer’s Disease Diagnostics & Treatment Market Revenues to Reach US$11.9 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Persistence Market Research
17 janv. 2024 05h00 HE
|
Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Market Size & Overview: The global market for Alzheimer's disease diagnostics and treatment is projected to experience a compound annual growth rate...
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
20 sept. 2023 13h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the...
Enhancing Care: Expansion of Alpers Disease Treatment Market Size On its Path to US$ 1.90 Billion by 2030, at a 4.57% of CAGR.
07 juin 2023 09h13 HE
|
Zion Market Research
Houston, TX, June 07, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Alpers Disease Treatment Market By Diagnosis (Molecular Genetic Testing, Laboratory...
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
26 avr. 2023 04h00 HE
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
19 avr. 2023 04h00 HE
|
NRG Therapeutics Limited
Vad Lazari Ph.D., appointed to the newly created position of VP of Biology, based in Stevenage, UKJoins from Charles River and brings two decades of drug discovery experience including at Pfizer and...
NRG Therapeutics Announces International Scientific Advisory Board
30 mars 2023 04h00 HE
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of...
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
09 févr. 2023 04h01 HE
|
NRG Therapeutics Limited
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UKJoins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at...
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
04 janv. 2023 16h15 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...